Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Van Ness

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Molecular and Cellular Biology|July 1, 1985
Nonproductive kappa immunoglobulin genes: recombinational abnormalities and other lesions affecting transcription, RNA processing, turnover, and translationD E Kelley, L M Wiedemann, A C Pittet, et al.
Cancer|September 24, 1999
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486M M Oken, T Leong, R E Lenhard, et al.
Blood|June 22, 2001
Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patientsN E Kay, T L Leong, N Bone, et al.
Leukemia|December 30, 2015
Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumorsA K Mitra, U K Mukherjee, T Harding, et al.
Blood|April 18, 1998
Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory GroupP R Greipp, T Leong, J M Bennett, et al.
Leukemia|June 22, 2001
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomyR Fonseca, M M Oken, D Harrington, et al.
Blood Cancer Journal|July 1, 2017
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaA K Mitra, T Harding, U K Mukherjee, et al.
Leukemia|January 12, 2007
Clinical significance of TP53 mutation in myelomaW J Chng, T Price-Troska, N Gonzalez-Paz, et al.
Leukemia|June 6, 2008
Clinical and biological significance of RAS mutations in multiple myelomaW J Chng, N Gonzalez-Paz, T Price-Troska, et al.
Leukemia|August 7, 2009
Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myelomaB G M Durie, B Van Ness, C Ramos, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Molecular and Cellular Biology|July 1, 1985
Nonproductive kappa immunoglobulin genes: recombinational abnormalities and other lesions affecting transcription, RNA processing, turnover, and translationD E Kelley, L M Wiedemann, A C Pittet, et al.
Cancer|September 24, 1999
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486M M Oken, T Leong, R E Lenhard, et al.
Blood|June 22, 2001
Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patientsN E Kay, T L Leong, N Bone, et al.
Leukemia|December 30, 2015
Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumorsA K Mitra, U K Mukherjee, T Harding, et al.
Blood|April 18, 1998
Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory GroupP R Greipp, T Leong, J M Bennett, et al.
Leukemia|June 22, 2001
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomyR Fonseca, M M Oken, D Harrington, et al.
Blood Cancer Journal|July 1, 2017
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaA K Mitra, T Harding, U K Mukherjee, et al.
Leukemia|January 12, 2007
Clinical significance of TP53 mutation in myelomaW J Chng, T Price-Troska, N Gonzalez-Paz, et al.
Leukemia|June 6, 2008
Clinical and biological significance of RAS mutations in multiple myelomaW J Chng, N Gonzalez-Paz, T Price-Troska, et al.
Leukemia|August 7, 2009
Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myelomaB G M Durie, B Van Ness, C Ramos, et al.
Pageof 7